Waffles thanks for another great in depth reply,
So it looks like like VK5211 is our Best solid Bet and 1-3 years is plenty of time before Warrants expire, especially if its fast tracked.
Thanks for the Lipid drug info, so it looks like that will be our wildcard drug, the potential is there and will have to play it out and also deal with competitors ....as where VK5211 seems like more of a Lock as far as meeting FDA endpoints as well as using it for other indications besides just Hip fractures and they are the only ones with a drug for it.
you would think a SARM would be safer and the best thing since sliced bread with all the other side effects some steroids put out there....same goes for thyroid beta agonist. The FDA should like this type of drugs and favor them over others.
" Once little guy traders want this stock, the big guys will not loner be able to resist the chance to get in and screw with it. There will be a big initial jump when one of them enters"
" guess it all depends on how many shares there are at that point. If we hit two home runs on phase two, and get a break with how quickly the orphan indication can progress, I could easily see a 200 mil market cap by mid next year.
All bets are off though with such a low float, that's just what I've seen before with similar stuff. I made some of my original cash on diet drugs a couple of years ago, and those guys were startups who briefly attained 1 billion dollars caps. It's totally doable, ""
Thankyou , sounds good Waffles,
BTW had some Waffles the other day at IHOP with blueberries, they were good .
GLTU and all here
News 
Market Data 
Discover 
